{"disease":{"id":"acute-disease","name":"acute disease"},"drugs":{"marketed":[{"drug_id":"ruxolitinib","indication_name":"Acute graft-versus-host disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jakafi","generic_name":"RUXOLITINIB","company_name":"Incyte Corp","drug_phase":"marketed","molecular_target":"Ankyrin repeat and protein kinase domain-containing protein 1, Bone morphogenetic protein receptor type-1B, Calcium/calmodulin-dependent protein kinase type IV","drug_class":"","quality_score":null,"revenue":"2600","mechanism":null},{"drug_id":"venetoclax","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venclexta","generic_name":"venetoclax","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Apoptosis regulator Bcl-2","drug_class":"BCL-2 Inhibitor [EPC]","quality_score":80,"revenue":"2583","mechanism":"Venclexta is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein."},{"drug_id":"cyclophosphamide","indication_name":"Acute lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"gilteritinib","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xospata","generic_name":"GILTERITINIB","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Leukocyte tyrosine kinase receptor","drug_class":"","quality_score":65,"revenue":"600","mechanism":"Xospata works by blocking the activity of a specific enzyme called Leukocyte tyrosine kinase receptor."},{"drug_id":"midostaurin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rydapt","generic_name":"MIDOSTAURIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Mast/stem cell growth factor receptor Kit","drug_class":"Kinase Inhibitor [EPC]","quality_score":62,"revenue":"200","mechanism":"Rydapt blocks the activity of the Kit receptor, which is involved in the growth and survival of cancer cells."},{"drug_id":"glasdegib","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daurismo","generic_name":"glasdegib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Smoothened homolog","drug_class":"Hedgehog Pathway Inhibitor [EPC]","quality_score":10,"revenue":"150","mechanism":"Daurismo works by blocking the Smoothened homolog, a protein involved in the Hedgehog signaling pathway, which is often dysregulated in cancer cells."},{"drug_id":"daurismo","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daurismo","generic_name":"Glasdegib Maleate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Smoothened (transmembrane protein)","drug_class":"Hedgehog pathway inhibitor","quality_score":10,"revenue":"150","mechanism":"Glasdegib inhibits Smoothened, a transmembrane protein in the Hedgehog signaling pathway."},{"drug_id":"mylotarg","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mylotarg","generic_name":"Gemtuzumab Ozogamicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD33 antigen","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"100","mechanism":"CD33-directed antibody-drug conjugate that delivers cytotoxic calicheamicin to tumor cells."},{"drug_id":"gemtuzumab-ozogamicin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mylotarg","generic_name":"gemtuzumab-ozogamicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Myeloid cell surface antigen CD33","drug_class":"CD33-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"100","mechanism":"Mylotarg works by binding to CD33 on cancer cells and releasing a toxic compound that kills the cells."},{"drug_id":"histamine","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eramin","generic_name":"HISTAMINE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"histamine","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Acute Bacterial Exacerbation of Chronic Obstructive Pulmonary Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"cytarabine","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytarabine","generic_name":"Cytarabine","company_name":"Nippon Shinyaku Co., Ltd.","drug_phase":"marketed","molecular_target":"DNA polymerase","drug_class":"Antimetabolite","quality_score":72,"revenue":null,"mechanism":"Cytarabine inhibits DNA polymerase and incorporates into DNA/RNA, killing cells in S-phase."},{"drug_id":"adriacin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"aclacinomycin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"aclacinomycin","company_name":"Chinese PLA General Hospital","drug_phase":"phase_3","molecular_target":"72 kDa type IV collagenase, DNA topoisomerase II, 5-hydroxytryptamine receptor 2B","drug_class":"","quality_score":4,"revenue":null,"mechanism":null},{"drug_id":"cyclophosphamid","indication_name":"Acute lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"enasidenib","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idhifa","generic_name":"ENASIDENIB","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Isocitrate dehydrogenase [NADP], mitochondrial","drug_class":"Isocitrate Dehydrogenase 2 Inhibitor","quality_score":59,"revenue":null,"mechanism":"Idhifa works by blocking the IDH2 enzyme, which is mutated in some AML cells, to prevent the production of a toxic metabolite that promotes cancer growth."},{"drug_id":"azacytidine","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"azacytidine","company_name":"Assistance Publique Hopitaux De Marseille","drug_phase":"marketed","molecular_target":"DNA (cytosine-5)-methyltransferase 1, DNA (cytosine-5)-methyltransferase 3A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"atm-avi","indication_name":"Treatment of acute bacterial exacerbation of chronic obstructive pulmonary disease (ABECOPD) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of acute bacterial exacerbation of chronic obstructive pulmonary disease (ABECOPD) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"nitroglycerin","indication_name":"Acute relief of angina pectoris due to coronary artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NITROGLYCERIN","company_name":"","drug_phase":"marketed","molecular_target":"Nitric oxide synthase pathway","drug_class":"Nitrate Vasodilator [EPC]","quality_score":10,"revenue":null,"mechanism":"Nitroglycerin forms nitric oxide, which activates guanylate cyclase, leading to increased cyclic GMP and subsequent vasodilation in smooth muscle."},{"drug_id":"aclarubicin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aclacur","generic_name":"ACLARUBICIN","company_name":"","drug_phase":"phase_3","molecular_target":"5-hydroxytryptamine receptor 2B","drug_class":"aclarubicin","quality_score":null,"revenue":null,"mechanism":"Aclacur works by binding to the 5-hydroxytryptamine receptor 2B, which is involved in cell growth and proliferation."},{"drug_id":"mitoxantrone","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."},{"drug_id":"thioguanine","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thioguanine","generic_name":"thioguanine","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1","drug_class":"thioguanine","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl1200976","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idamycin Pfs","generic_name":"IDARUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"DNA, topoisomerase II","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":75,"revenue":null,"mechanism":"Idarubicin hydrochloride exerts its effects by forming DNA complexes, inhibiting nucleic acid synthesis, blocking topoisomerase II, and generating DNA-damaging free radicals."},{"drug_id":"ivosidenib","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tibsovo","generic_name":"IVOSIDENIB","company_name":"Servier","drug_phase":"marketed","molecular_target":"mutant IDH1","drug_class":"Isocitrate Dehydrogenase 1 Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Ivosidenib inhibits mutant IDH1, reducing 2-HG levels and promoting myeloid differentiation in AML."},{"drug_id":"aldesleukin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Proleukin","generic_name":"ALDESLEUKIN","company_name":"Chiron","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"Lymphocyte Growth Factor [EPC]","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"olutasidenib","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rezlidhia","generic_name":"OLUTASIDENIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"mutated IDH1","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Olutasidenib inhibits mutated IDH1, reducing 2-HG levels in AML cells."},{"drug_id":"doxorubicin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"idarubicin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idamycin Pfs","generic_name":"IDARUBICIN","company_name":"","drug_phase":"marketed","molecular_target":"DNA topoisomerase 2-alpha","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Idarubicin works by binding to DNA topoisomerase 2-alpha, preventing the enzyme from unwinding DNA and leading to cell death."},{"drug_id":"chembl-chembl1200796","indication_name":"Acute lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"fludarabin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fludarabin","company_name":"Azienda Ospedaliera San Giovanni Battista","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xospata","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xospata","company_name":"French Innovative Leukemia Organisation","drug_phase":"marketed","molecular_target":"ADP/ATP translocase 2, ADP/ATP translocase 3, Bone morphogenetic protein receptor type-1B","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"proleukin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Proleukin","company_name":"University of Minnesota","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fludara","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fludara","company_name":"Celyad Oncology SA","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mitozantrone","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mitozantrone","company_name":"US Department of Veterans Affairs","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family G member 2, DNA-(apurinic or apyrimidinic site) lyase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunomycin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"decitabine","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dacogen","generic_name":"decitabine","company_name":"Sun Pharma","drug_phase":"marketed","molecular_target":"DNA (cytosine-5)-methyltransferase 1","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":58,"revenue":null,"mechanism":"Dacogen works by inhibiting the enzyme that adds methyl groups to DNA, which helps to restore normal gene function in cancer cells."},{"drug_id":"daunorubicin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daunorubicin Hydrochloride","generic_name":"daunorubicin","company_name":"Meiji Seika Pharma Co., Ltd","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"azacitidine","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vidaza","generic_name":"azacitidine","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"DNA (cytosine-5)-methyltransferase 1","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":61,"revenue":null,"mechanism":"Vidaza works by incorporating itself into DNA and interfering with the enzyme that adds methyl groups, which helps to restore normal gene function in cancer cells."},{"drug_id":"quizartinib","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vanflyta","generic_name":"QUIZARTINIB","company_name":"Daiichi Sankyo Inc","drug_phase":"marketed","molecular_target":"Macrophage colony-stimulating factor 1 receptor","drug_class":"","quality_score":75,"revenue":null,"mechanism":"Vanflyta works by blocking the macrophage colony-stimulating factor 1 receptor, which is involved in the growth and survival of cancer cells."},{"drug_id":"fludarabine-phosphate","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludara","generic_name":"FLUDARABINE PHOSPHATE","company_name":"Nihon Schering K.K.","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial","drug_class":"Nucleoside Metabolic Inhibitor","quality_score":65,"revenue":null,"mechanism":"Fludara works by interfering with the production of DNA and RNA in cancer cells, ultimately leading to cell death."},{"drug_id":"idarubicin-hydrochloride","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idamycin Pfs","generic_name":"Idarubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA, Topoisomerase II","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":61,"revenue":null,"mechanism":"Idarubicin forms DNA complexes, inhibits nucleic acid synthesis and topoisomerase II, produces DNA-damaging free radicals."},{"drug_id":"dacogen","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dacogen","company_name":"Mayo Clinic","drug_phase":"discontinued","molecular_target":"DNA (cytosine-5)-methyltransferase 1, DNA (cytosine-5)-methyltransferase 3A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"daunorubicine","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daunorubicine","company_name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","drug_phase":"discontinued","molecular_target":"Multidrug resistance-associated protein 6, 72 kDa type IV collagenase, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":47,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05198492","title":"Short- and Long-term Health Effects of Air Pollution in Poland","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8300000,"lead_sponsor_name":"Medical University of Bialystok","has_results":false},{"nct_id":"NCT06239129","title":"The Stockholm CREAtinine Measurements Project","phase":"","overall_status":"COMPLETED","enrollment_count":3200000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT07080086","title":"The Effect of Preoperative Biological Age on Hemodynamics and Renal Function","phase":"","overall_status":"COMPLETED","enrollment_count":268833,"lead_sponsor_name":"Nanjing First Hospital, Nanjing Medical University","has_results":false},{"nct_id":"NCT04571021","title":"Implementation of the Individual Danish Emergency Process Triage","phase":"NA","overall_status":"COMPLETED","enrollment_count":250000,"lead_sponsor_name":"Herlev Hospital","has_results":false},{"nct_id":"NCT07416266","title":"Lower Respiratory Tract Infections Managed in Primary Care in France","phase":"","overall_status":"COMPLETED","enrollment_count":230066,"lead_sponsor_name":"Hôpital Raymond Poincaré","has_results":false},{"nct_id":"NCT04541498","title":"Impact of Air Pollution and Climate Changes on the Epidemiology of Cardiovascular Disease","phase":"","overall_status":"COMPLETED","enrollment_count":150000,"lead_sponsor_name":"Medical University of Bialystok","has_results":false},{"nct_id":"NCT04008173","title":"The International Survey of Acute Coronary Syndromes-ARCHIVES","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":130000,"lead_sponsor_name":"University of Bologna","has_results":false},{"nct_id":"NCT05151003","title":"Epidemiology of In-hospital Acute Kidney Injury","phase":"","overall_status":"UNKNOWN","enrollment_count":60000,"lead_sponsor_name":"Universita degli Studi di Genova","has_results":false},{"nct_id":"NCT03258983","title":"Alpha-linolenic Acid and the Risk of ASCVD","phase":"","overall_status":"COMPLETED","enrollment_count":57053,"lead_sponsor_name":"Aalborg University Hospital","has_results":false},{"nct_id":"NCT01218776","title":"International Survey of Acute Coronary Syndromes","phase":"","overall_status":"RECRUITING","enrollment_count":36000,"lead_sponsor_name":"University of Bologna","has_results":false},{"nct_id":"NCT04615065","title":"Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT06265714","title":"The IndONEsia ICCU Registry: a Multicenter Cohort of Intensive Cardiovascular Care Units Patients in Indonesia","phase":"","overall_status":"COMPLETED","enrollment_count":12950,"lead_sponsor_name":"Indonesia University","has_results":false},{"nct_id":"NCT02111564","title":"A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":12024,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT03832257","title":"Improving Safety of Transitions to Skilled Nursing Care Using Videoconferencing","phase":"NA","overall_status":"COMPLETED","enrollment_count":10708,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false},{"nct_id":"NCT06489080","title":"Survival and cArdiovascular eVents in Patients With Acute Myocardial Infarction","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT06652776","title":"The Italian Registry of Patients With Chronic Obstructive Pulmonary Disease","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10000,"lead_sponsor_name":"University of Milan","has_results":false},{"nct_id":"NCT05681962","title":"Practice of Oxygenation and Respiratory Support During Fiberoptic Bronchoscopy","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"University Magna Graecia","has_results":false},{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT04624854","title":"Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":8250,"lead_sponsor_name":"Harbin Medical University","has_results":false},{"nct_id":"NCT05097677","title":"Follow-up of Covid-19 Long Term Sequelae","phase":"","overall_status":"COMPLETED","enrollment_count":7599,"lead_sponsor_name":"Azienda Ospedaliera Universitaria Integrata Verona","has_results":false},{"nct_id":"NCT05336435","title":"A Study of Population and Sex-specific Troponin Cutoffs for Ruling Out Acute Myocardial Infarction","phase":"NA","overall_status":"UNKNOWN","enrollment_count":7500,"lead_sponsor_name":"Herlev Hospital","has_results":false},{"nct_id":"NCT05766046","title":"Lung Cancer Prevention Screening Programme in Italy","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":7324,"lead_sponsor_name":"Ugo Pastorino","has_results":false},{"nct_id":"NCT03453996","title":"Contrast RISK (Reducing Injury Sustained by Kidneys)","phase":"NA","overall_status":"COMPLETED","enrollment_count":7280,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT04676100","title":"International CR Registry","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":7000,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT04367740","title":"ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":6313,"lead_sponsor_name":"University of North Carolina, Chapel Hill","has_results":false},{"nct_id":"NCT04627623","title":"Prevalence and Risk Factors of COVID-19 in the Upper Silesian Agglomeration","phase":"","overall_status":"UNKNOWN","enrollment_count":6000,"lead_sponsor_name":"Medical University of Silesia","has_results":false},{"nct_id":"NCT01467466","title":"Prevention of Serious Adverse Events Following Angiography","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":5177,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT05222074","title":"Effect of CVP and IOH on AKI and AKD","phase":"","overall_status":"COMPLETED","enrollment_count":5127,"lead_sponsor_name":"Nanjing First Hospital, Nanjing Medical University","has_results":false},{"nct_id":"NCT03252249","title":"Duration of Dual Anti-Platelet Therapy (DUAL-ACS)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":5094,"lead_sponsor_name":"University of Edinburgh","has_results":true},{"nct_id":"NCT03633838","title":"Clinical Outcome of Corticosteroids in the Treatment of COPD Exacerbations in China","phase":"","overall_status":"COMPLETED","enrollment_count":5067,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07445763","title":"TARSILA Real-World Evidence Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Inova Medical","has_results":false},{"nct_id":"NCT05318196","title":"Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT03592563","title":"CUHK Brain Health Longitudinal Study","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT06162247","title":"Naples Federico II Intensive Cardiac Care Unit Registry (Naples FED2-ICCU Registry)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Federico II University","has_results":false},{"nct_id":"NCT07472335","title":"Home-based Acute Care for Older Persons Initiated by the Emergency Medical and Ambulance Services - a Retrospective Observation of Effects on Healthcare Utilisation and Mortality","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Vastra Gotaland Region","has_results":false},{"nct_id":"NCT01740479","title":"Complete vs Culprit-only Revascularization to Treat Multi-vessel Disease After Early PCI for STEMI","phase":"NA","overall_status":"COMPLETED","enrollment_count":4042,"lead_sponsor_name":"Population Health Research Institute","has_results":false},{"nct_id":"NCT07070362","title":"Digital Early Warning System for Acute Lung Injury in Liver Surgery","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"Beijing Tsinghua Chang Gung Hospital","has_results":false},{"nct_id":"NCT07385482","title":"Chronic and Acute Cardiovascular Diseases in Elderly Intensive Care Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":4000,"lead_sponsor_name":"Heinrich-Heine University, Duesseldorf","has_results":false},{"nct_id":"NCT05166447","title":"Twenty-year Follow-up of the Inter99 Cohort","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":4000,"lead_sponsor_name":"Bispebjerg Hospital","has_results":false},{"nct_id":"NCT05515653","title":"Impact of the Genetic Background as a Risk Factor for Atherosclerotic Cardiovascular Disease in the Brazilian Population","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3974,"lead_sponsor_name":"Hospital Alemão Oswaldo Cruz","has_results":false},{"nct_id":"NCT06320730","title":"Impact of Glycemic Control After Reperfusion on Acute Kidney Injury in Living Donor Liver Transplantation","phase":"","overall_status":"COMPLETED","enrollment_count":3790,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT01674803","title":"Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion (BIO-RESORT)","phase":"NA","overall_status":"COMPLETED","enrollment_count":3514,"lead_sponsor_name":"Foundation of Cardiovascular Research and Education Enschede","has_results":false},{"nct_id":"NCT07354828","title":"Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Shenyang Northern Hospital","has_results":false},{"nct_id":"NCT06340607","title":"Neohepatic Albumin-Bilirubin Scores on Renal Outcomes in Living-donor Liver Transplantation Recipients","phase":"","overall_status":"COMPLETED","enrollment_count":3422,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT05062967","title":"Evaluation of Orthohepevirus C Infection as an Emerging Cause of Zoonotic Origin Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":3257,"lead_sponsor_name":"Maimónides Biomedical Research Institute of Córdoba","has_results":false},{"nct_id":"NCT07182799","title":"Starring Optical Coherence Tomography During Percutaneous Coronary Intervention Guidance","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3200,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT07252544","title":"Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":3156,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT05913700","title":"Effect of Respiratory Virus Infection on EmeRgencY Admission Study (EVERY Study)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3067,"lead_sponsor_name":"Institute for Clinical Effectiveness, Japan","has_results":false},{"nct_id":"NCT03462498","title":"ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3008,"lead_sponsor_name":"Kyoto University, Graduate School of Medicine","has_results":false},{"nct_id":"NCT03329768","title":"Evaluation of Medical Device","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}